Diagnostic utility of CSF α-synuclein species in Parkinson's disease: Protocol for a systematic review and meta-analysis

BMJ Open

Volumn 6, Issue 6, 2016, Pages

  Eusebi, Paolo ^a,b   Giannandrea, David ^c   Biscetti, Leonardo ^a   Abraha, Iosief ^b   Chiasserini, Davide ^a   Orso, Massimiliano ^b   Calabresi, Paolo ^a,d   Parnetti, Lucilla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Regional Health Authority of Umbria   (Italy)

^c Gubbio and Gualdo Tadino Hospital   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

diagnostics; meta analysis; systematic review; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ATROPHY; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CORTICOBASAL DEGENERATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; HUMAN; META ANALYSIS; PARKINSON DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; SHY DRAGER SYNDROME; SYSTEMATIC REVIEW; DIFFERENTIAL DIAGNOSIS; LEWY BODY; METHODOLOGY; PATHOLOGY;

ALPHA-SYNUCLEIN; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODIES; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; RESEARCH DESIGN;

EID: 84975774497     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-011113     Document Type: Review

References (27)

1. Uversky VN. Alpha-synuclein misfolding and neurodegenerative diseases. Curr Protein Pept Sci 2008;9:507-40.
2. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2014;29:1583-90.
3. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-66.
4. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
5. Munhoz RP, Moro A, Silveira-Moriyama L, et al. Non-motor signs in Parkinson's disease: a review. Arq Neuropsiquiatr 2015;73:454-62.
6. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-80.
7. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70.
8. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013;9:131-40.
9. Spillantini MG, Crowther RA, Jakes R, et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-73.
10. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011;10:230-40.
11. Aerts MB, Esselink RA, Abdo WF, et al. CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 2012;33:430.e1-3.
12. Hall S, Öhrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-52.
13. Magdalinou NK, Paterson RW, Schott JM, et al. A panel of nine cerebrospinal fluid biomarkers May identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatr 2015;86:1240-7.
14. Gao L, Tang H, Nie K, et al. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis. Int J Neurosci 2015;125:645-54.
15. Sako W, Murakami N, Izumi Y, et al. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis. Mov Disord 2014;29:1599-605.
16. Zhou B, Wen M, Yu WF, et al. The diagnostic and differential diagnosis utility of cerebrospinal fluid α-Synuclein levels in Parkinson's disease: a meta-analysis. Parkinsons Dis 2015;2015:567386.
17. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
18. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72.
19. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670-6.
20. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
21. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97-105.
22. Alexander SK, Rittman T, Xuereb JH, et al. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatr 2014;85:925-9.
23. Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496-503.
24. Bak TH, Hodges JR. Corticobasal degeneration: clinical aspects. Handb Clin Neurol. 2008;89:509-21. doi:10.1016/S0072-9752(07) 01247-X
25. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatr 1992;55:181-4.
26. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
27. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90.